Determinants of prostate cancer specific survival following radiation therapy during the prostate specific antigen era

Journal of Urology

Volumn 170, Issue 6 II, 2003, Pages

  D'Amico, Anthony V ^a   Cote, Kerri ^a   Loffredo, Marian ^a   Renshaw, Andrew A ^a   Schultz, Delray ^b   Roach III, Mack ^c   Kantoff, Philip W ^c   Smith, Matthew R ^c   Nelson, Joel B ^c   Carroll, Peter ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Department of Mathematics   (United States)

^c Brigham and Women's Hospital ^*

Author keywords

Outcome study; Prostate specific antigen; Prostatic neoplasms; Radiation therapy; Survival analysis

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONFERENCE PAPER; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; REGRESSION ANALYSIS;

EID: 0242692716     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000094800.63501.15     Document Type: Conference Paper

References (18)

1. Han, M., Partin, A. W., Zahurak, M., Piantadosi, S., Epstein, J. I. and Walsh, P. C.: Biochemical (PSA) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol, 169: 517, 2003
2. Shipley, W. U., Thames, H. D., Sandler, H. M., Hanks, G. E., Zietman, A. L., Perez, C. A. et al: Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA, 281: 1598, 1999
3. D'Amico, A. V., Whittington, R., Malkowicz, S. B., Schultz, D., Tomaszewski, J. E., Kaplan, I. et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA, 280: 969, 1998
4. Kattan, M. W., Easthan, J. A., Stapleton, A. M. F., Wheeler, T. M. and Scardino, P. T.: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. JNCI, 90: 766, 1998
5. Albertsen, P. C., Hanley, J. A., Gleason, D. F. and Barry, M. J.: Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA, 280: 975, 1998
6. Pound, C. R., Partin, A. W., Eisenberger, M. A., Chan, D. W., Pearson, J. D. and Walsh, P. C.: Natural history of progression after PSA elevation following radical prostatectomy. JAMA, 281: 1591, 1999
7. Lee, W. R., Hanks, G. E. and Hanlon, A.: Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. J Clin Oncol, 15: 230, 1997
8. Dearnaley, D., Khoo, V., Norman, A., Meyer, L., Nahum, A., Tait, D. et al: Comparison of radiation side effects of conformal and conventional radiotherapy in prostate cancer: a randomized trial. Lancet, 353: 267, 1999
9. Consensus statement: Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys, 37: 1035, 1997
10. Neter, J., Wasserman, W. and Kutner, M.: Simultaneous inferences and other topics in regression analysis-1. In: Applied Linear Regression Models. Homewood, Illinois: Richard D. Irwin, Inc., pp. 150-153, 1983
11. Sandler, H. M., Dunn, R. L., McLaughlin, P. W., Hayman, J. A., Sullivan, M. A. and Taylor, J. M.: Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys, 48: 629, 2000
12. Kaplan, E. L. and Meier, P.: Non-parametric estimation from incomplete observations. J Am Stat Assoc, 53: 457, 1958
13. Gaynor, J. J., Feur, E. J., Tan, C. C., Wu, D. H., Little, C. R., Straus, D. J. et al: On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data. J Am Stat Assoc, 88: 400, 1993
14. Bolla, M., Collette, L., Blank, L., Warde, P., Dubois, J. B., Mirimanoff, R. et al: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet, 360: 103, 2002
15. Patel, A., Dorey, F., Franklin, J. and deKernion, J. B.: Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol, 158: 1441, 1997
16. Roberts, S. G., Blute, M. L., Bergstralh, E. J., Slezak, J. M. and Zincke, H.: PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc, 76: 576, 2001
17. Sartor, C. I., Strawderman, M. H., Lin, X. H., Kish, K. E., McLaughlin, P. W. and Sandler, H. M.: Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int J Radiat Oncol Biol Phys, 38: 941, 1997
18. Prentice, R. L.: Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med, 8: 431, 1989